Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Fan-Li Lin, Peng-Yuan Wang, Yu-Fan Chuang, Jiang-Hui Wang, Vickie HY Wong, Bang Bui, Guei-Sheung Liu
Molecular Therapy | CELL PRESS | Published : 2020
Aberrant growth of blood vessels (neovascularization) is a key feature of severe eye diseases that can cause legal blindness, including neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR). The development of anti-vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of ocular neovascularization. Novel proangiogenic targets, such as angiopoietin and platelet-derived growth factor (PDGF), are under development for patients who respond poorly to anti-VEGF therapy and to reduce adverse effects from long-term VEGF inhibition. A rapidly advancing area is gene therapy, which may provide significant therapeutic benefits. Viral vector-mediated..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation
This work was supported by grants from the National Health and Medical Research Council of Australia (GNT1185600), the Ophthalmic Research Institute of Australia, and the Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation (ZDSYS20190902093409851). The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.